111 related articles for article (PubMed ID: 10464923)
1. Absorbed doses to patients from 191Pt-, 193mPt- and 195mPt-cisplatin.
Areberg J; Norrgren K; Mattsson S
Appl Radiat Isot; 1999 Nov; 51(5):581-6. PubMed ID: 10464923
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Imaging agent for single photon emission computed tomography.
Sathekge M; Wagener J; Smith SV; Soni N; Marjanovic-Painter B; Zinn C; Van de Wiele C; D'Asseler Y; Perkins G; Zeevaart JR
Nuklearmedizin; 2013 Dec; 52(6):222-7. PubMed ID: 24108524
[TBL] [Abstract][Full Text] [Related]
3. Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin.
Areberg J; Björkman S; Einarsson L; Frankenberg B; Lundqvist H; Mattsson S; Norrgren K; Scheike O; Wallin R
Acta Oncol; 1999; 38(2):221-8. PubMed ID: 10227445
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
5. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
6. Local distribution into brain tumor and pharmacokinetics of 4-pyridoxate diammine hydroxy platinum, a novel cisplatin derivative, after intracarotid administration in rats with 9L malignant glioma: simultaneous brain microdialysis study.
Tokunaga Y; Nakashima M; Sasaki H; Tomiyama N; Nakashima MN; Ichikawa M; Kaminogo M; Shibata S
Biol Pharm Bull; 2000 Dec; 23(12):1491-6. PubMed ID: 11145184
[TBL] [Abstract][Full Text] [Related]
7. Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport.
Tolvanen T; Någren K; Yu M; Sutinen E; Havu-Aurén K; Jyrkkiö S; Asola M; Kotoneva E; Nuutila P; Minn H
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1178-84. PubMed ID: 16721566
[TBL] [Abstract][Full Text] [Related]
8. Radiotoxicity of platinum-195m-labeled trans-platinum (II) in mammalian cells.
Howell RW; Kassis AI; Adelstein SJ; Rao DV; Wright HA; Hamm RN; Turner JE; Sastry KS
Radiat Res; 1994 Oct; 140(1):55-62. PubMed ID: 7938455
[TBL] [Abstract][Full Text] [Related]
9. Comparative renal, hepatic, and bone marrow toxicity of Cisplatin and radioactive Cisplatin (191Pt) in Wistar rats.
Norrgren K; Sjölin M; Björkman S; Areberg J; Johnsson A; Johansson L; Mattsson S
Cancer Biother Radiopharm; 2006 Oct; 21(5):528-34. PubMed ID: 17105425
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
11. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
12. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
13. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.
Los G; Mutsaers PH; Lenglet WJ; Baldew GS; McVie JG
Cancer Chemother Pharmacol; 1990; 25(6):389-94. PubMed ID: 2311166
[TBL] [Abstract][Full Text] [Related]
14. In vitro toxicity of (191)Pt-labeled cisplatin to a human cervical carcinoma cell line (ME-180).
Areberg J; Johnsson A; Wennerberg J
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1275-80. PubMed ID: 10725641
[TBL] [Abstract][Full Text] [Related]
15. Novel weight-based dose threshold for 18F-NaF PET-CT imaging using advanced PET-CT systems: a potential tool for reducing radiation burden.
Marafi F; Esmail A; Rasheed R; Alkandari F; Usmani S
Nucl Med Commun; 2017 Sep; 38(9):764-770. PubMed ID: 28723715
[TBL] [Abstract][Full Text] [Related]
16. Distribution of platinum in human gynecologic tissues and pelvic lymph nodes after administration of cisplatin.
Tokuhashi Y; Kikkawa F; Ishikawa H; Tamakoshi K; Hattori S; Matsuzawa K; Inoue T; Suganuma N; Tomoda Y
Gynecol Obstet Invest; 1997; 44(4):270-4. PubMed ID: 9415527
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans.
Shani J; Bertram J; Russell C; Dahalan R; Chen DC; Parti R; Ahmadi J; Kempf RA; Kawada TK; Muggia FM
Cancer Res; 1989 Apr; 49(7):1877-81. PubMed ID: 2924326
[TBL] [Abstract][Full Text] [Related]
19. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET.
Laforest R; Dehdashti F; Lewis JS; Schwarz SW
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):764-70. PubMed ID: 15785955
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of radioactive cisplatin (191Pt) on nude mice.
Areberg J; Wennerberg J; Johnsson A; Norrgren K; Mattsson S
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):827-32. PubMed ID: 11172966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
